Skip to main content
Monday, November 16, 2026Nov 16

Patients praise Regeneron as antibody treatments continue in Dalton, Georgia

Staff Photo by Matt Hamilton / Dalton Fire Department paramedic Michael Sams injects the monoclonal antibody treatment into the abdomen of Cartersville resident Mitch Lowery on Wednesday. The Regeneron clinic provided the monoclonal antibody treatment in a drive-thru setting at the Dalton Convention Center parking lot on Wednesday, September 1, 2021.
Staff Photo by Matt Hamilton / Dalton Fire Department paramedic Michael Sams injects the monoclonal antibody treatment into the abdomen of Cartersville resident Mitch Lowery on Wednesday. The Regeneron clinic provided the monoclonal antibody treatment in a drive-thru setting at the Dalton Convention Center parking lot on Wednesday, September 1, 2021.

DALTON, Ga. – More than 400 people have been injected with monoclonal antibodies in Dalton over the past week as health officials and city leaders attempt to mitigate the late summer surge of COVID-19 that has overwhelmed North Georgia hospitals and schools.

The treatment, commonly referred to as the brand name Regeneron, can be given to early diagnosed COVID-19 patients and has been shown to reduce hospitalizations or deaths when administered within seven days of the first onset of illness.

In the past, the treatment was administered intravenously and on an outpatient basis only. That changed in June when it became possible to administer through a series of four injections.

Regeneron treatments then became much more widely available. Annalee Harlan, a Dalton City Council member and former paramedic who owns and operates a local hospice company, immediately began to push for the city to get involved in the treatments.

By the end of August, the convention center parking lot in Dalton had been transformed into a drive-through clinic, and local firefighters, paramedics, emergency medical technicians and volunteers were charged with administering the injections. Thanks to a partnership with AmericsourceBergen, the therapy’s distributor, Harlan said there was “no outside expense for the procurement of the drug” on the part of the city. The cost of labor, syringes and other materials used to administer the treatment will come out of the city of Dalton’s general fund, though city spokesperson Bruce Frazier said the exact dollar amount that will be spent is not yet known.